A single day large increase is not able to prove a good stock, but we still like to focus on the top stock gainers, as they more or less show some speculative timings or buying opportunities.
Today’s top stock gainers are led by three medical stocks:AXK, RDEA, DHRM.
Accelr8 Technology (AXK) focuses on the research and development, and commercialization of an integrated system to identify bacteria and their mechanisms of antibiotic resistance in critically ill patients.
AXK stock price realized a huge increase of 141.32% or $2.51, to finish at $2.51 in Monday’s regular trading session, then the stock maintained the upward momentum in the after-hours trading, achieving an advance of 9.16%. Today’s performance was primarily due to Accelr8 attracted an amount of up to $35 million private equity investment in AXK stock from an investment group formed by Jack Schuler, John Patience, and Larry Mehren.
Ardea Biosciences (RDEA), a biotechnology company, focuses on the development of small-molecule therapeutics for the treatment of gout and cancer in the United States.
Ardea Biosciences saw its share price rising sharply by 51.2% to $31.51 at the openning of the market, after U.K. drug giant AstraZeneca agreed to purchase the biotech company for $1.26 billion, then RDEA stock price almost maintained this price level to the end of the market, to settle at $31.62, a slightly higher than the openning price.
Dehaier Medical Systems (DHRM) is focusing on designing, developing, and marketing its braned respiratory and oxygen homecare products, medical devices, and technical service products in China. The company imports the majority of the products and medical components it sells to its customers.
DHRM stock price surged 37.2%,or $0.83, to close at $3.06, as Dehaier Medical signed a strategic cooperation agreement with Timesco of London Ltd. to be the exclusive Chinese distributor for Timesco’s entire laryngoscope Optima series of products over the next three years.